Wegovy contains semaglutide, a medicine that acts like the natural hormone GLP-1
This is a series of Phase 3 trials studying retatrutide across multiple conditions: TRIUMPH-1 : Obesity (basket trial with nested OSA and OA protocols) TRIUMPH-2 : Obesity in type 2 diabetes population (with nested OSA) TRIUMPH-3 : Weight management in cardiovascular disease population TRIUMPH-4 : Obesity with knee osteoarthritis (completed results December 2025) Additional trials covering MASLD (metabolic dysfunction-associated steatotic liver disease), cardiovascular/renal outcomes, chronic low back pain, and weight maintenance TRANSCEND program: Dedicated type 2 diabetes trials (separate from TRIUMPH) TRIUMPH-4 was the first Phase 3 trial to report results, announced in December 2025
The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease
The study focused on physical fitness outcomes including stair climb performance, cardiorespiratory fitness, and knee extensor strength
3) If GLP-1s made people dizzy, then everyone would be complaining of dizziness and all the other GLP-1 side effects
